Online ISSN: 2515-8260

Keywords : human immunodeficiency virus (HIV)


Comparative Analysis Of The Frequency Of Occurrence Of The Ccr5del32 Functional Allele

Kadirov Jonibek Fayzullaevich; Rizaev Jasur Alimdjanovic; Khudaykulova Gulnara Karimovna; Rakhmatullaeva Shakhnoza Bakhadyrovn; Muminova Makhbuba Teshaevna

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 1008-1016

A promising area of modern medicine dealing with the problem of the human immunodeficiency virus (HIV) is the study of the role of chemokine receptors in the pathogenesis of HIV, such as CXCR-4 and CCR-5. A different role of the CCR5del32 polymorphism of the CCR5 gene in representatives of different ethnic groups has been established, which may cause different susceptibility to HIV.Purpose of the study is to carry out a comparative assessment of the frequency of occurrence of the functional allele "CCR5del32" of the CCR5 gene among different ethnic groups.To identify the delta32 deletion of the CCR5 gene, we used the RFLP approach of polymerase chain reaction followed by detection of the results by electrophoresis in 2% agarose gel.The obtained results of molecular genetic studies on the CCR5-Delta32 marker of the CCR5 gene are representative. The allelic variant "CCR5-Delta32" of the CCR5 gene within the studied populations is distributed unevenly and is most represented in the sample of Europeans. Comparative meta-analyzes show that the frequency of its occurrence among Europeans is significantly higher than in other populations of the world, including in comparison with our population.The relatively low concentration of the protective CCR5Δ32 allele in our population may lead to increased susceptibility to HIV-1 infection.

Dolutegravir, Second Generation Integrase Inhibitor: A New Hope for HIV Patient

Geeta Yadav; Piyush Kumar; Yugal Kumar; Pradeep Kumar Singh

European Journal of Molecular & Clinical Medicine, 2018, Volume 5, Issue 1, Pages 20-29

Undeterred efforts are reported and still continue in future to achieve the goals of virologic suppression in HIV-infected individuals. Dolutegravir is the result of all the efforts made in this direction. It is a recent integrase inhibitor drug approved by the US FDA (Food and Drug Administration) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of the drug, including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that can play an important role in the treating patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in the pipeline that can increase the immunologic response of the HIV patients.